NEW YORK, November 17, 2016 /PRNewswire/ --
Stock-Callers.com directs investors' attention to stocks in the Biotech space which are still valued more than 25% below their 2015 peak. According to analysts and investment bankers, a potential influx of foreign cash and improved stock valuations under the Trump's administration would likely boost M&A activities within the industry. Today, we have issued reports on the following equities: PDL BioPharma Inc. (NASDAQ: PDLI), Intrexon Corp. (NYSE: XON), 22nd Century Group Inc. (NYSE MKT: XXII), and Marinus Pharmaceuticals Inc. (NASDAQ: MRNS). You can access of our complimentary research reports on these stocks now at:
On Wednesday, shares in Incline Village, Nevada headquartered PDL BioPharma Inc. ended the session 18.01% lower at $3.05 with a total volume of 21.84 million shares traded. PDL BioPharma's shares have gained 9.32% in the last three months. The stock is trading 6.26% below its 50-day moving average and 4.74% below its 200-day moving average. Moreover, shares of the Company, which manages a portfolio of patents and royalty assets in the US and Europe, are trading at a PE ratio of 2.87 and have a Relative Strength Index (RSI) of 41.13.
On November 15th, 2016, PDL BioPharma announced that it intends to offer, subject to market and other conditions, $150 million aggregate principal amount of new convertible senior notes due December 1st, 2021 under PDL's shelf registration statement filed with the SEC on June 10, 2016, and declared effective by the SEC on June 28, 2016. PDL also expects to grant the underwriters a 12-day overallotment option to purchase up to an additional $22.5 million aggregate principal amount of Notes on the same terms and conditions. Visit us today and download your complete report on PDLI for free at:
Germantown, Maryland-based Intrexon Corp.'s stock finished Wednesday's session 6.61% lower at $30.50 with a total volume of 2.90 million shares traded. Over the last one month and the previous three months, Intrexon's shares have advanced 15.75% and 3.92%, respectively. Shares of the Company, which operates in the synthetic biology field in the US, are trading above its 50-day and 200-day moving averages by 11.04% and 5.23%, respectively. Intrexon's stock has an RSI of 61.58.
On November 09th, 2016, Intrexon reported total revenues of $49.0 million, a decrease of 8% from Q3 2015. The company posted net loss of $29.0 million attributed to Intrexon, or $(0.24) per basic share, including non-cash charges of $25.5 million. Cash, cash equivalents, and short-term and long-term investments totaled $280.7 million. The value of investment in preferred stock totaled $123.7 million and the value of equity securities totaled $39.4 million at September 30, 2016. The complimentary research report on XON can be accessed at:
22nd Century Group
On Wednesday, shares in Clarence, New York headquartered 22nd Century Group Inc. recorded a trading volume of 829,648 shares. The stock ended the day 3.36% higher at $1.15. 22nd Century's stock has advanced 6.48% in the last three months. Shares of the Company, which provides technology that allows for the level of nicotine and other nicotinic alkaloids in tobacco plants to be decreased or increased through genetic engineering and plant breeding, are trading above its 200-day moving average by 17.61%. Furthermore, 22nd Century Group's shares have an RSI of 42.83.
On November 08th, 2016, 22nd Century reported that net sales revenue for Q3 2016 was $3,098,000, an increase of $430,000, or 16.1%, over net sales revenue of $2,668,000 for Q3 2015. For Q3 2016, operating loss was $2,596,000 compared to an operating loss of $2,758,000 for Q3 2015. The Company's net loss for Q3 2016 was $2,680,000, or ($0.03) per share compared to a net loss of $2,762,000, or ($0.04) per share for Q3 2015. Register for free on Stock-Callers.com and download the PDF research report on XXII at:
Radnor, Pennsylvania-based Marinus Pharmaceuticals Inc.'s stock fell 1.71%, to close the day at $1.15. The stock recorded a trading volume of 503,372 shares. Shares of the Company, which focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders, are trading 24.47% and 63.99% below its 50-day and 200-day moving averages, respectively. Additionally, the stock has an RSI of 39.76.
On November 15th, 2016, Marinus Pharmaceuticals presented preclinical data showing that the combination of its CNS-selective GABAA modulator ganaxolone and diazepam administered intravenously (IV) produced a synergistic effect in blocking pilocarpine-induced seizures in a benzodiazepine refractory model of status epilepticus. Marinus is developing ganaxolone IV for the treatment of status epilepticus, a life-threatening medical emergency associated with high mortality and limited treatment options. Get free access to your research report on MRNS at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA